A New Era of Cancer Therapy Has Begun

Video Description

Over the past few months, several major biotech and pharmaceutical companies have made headlines with their advancements in multispecific protein therapeutics, a new class of drugs poised to challenge the dominance of Merck’s blockbuster oncology drug, Keytruda.

The landscape is shifting with the emergence of multispecific therapies, particularly bispecific antibodies that target multiple cancer pathways simultaneously. These therapies are showing great promise in head-to-head trials against Keytruda, and companies like Summit Therapeutics, AbbVie, BioNTech, and Merck itself are racing to develop or acquire these innovative treatments.

Here, I break down the science behind multispecifics, including T-cell engagers and combinatorial bispecifics, and highlight recent acquisitions and clinical results that are shaping the future of oncology. With big pharma heavily investing in this space, I predict we’ll see a surge in FDA approvals for these therapies over the next few years.

If you’re interested in staying ahead of trends in cancer treatment or want to understand how multispecific protein therapeutics are reshaping the field of oncology, this episode is for you.

Don’t forget to share your thoughts with me or pass this video along to colleagues who might find it valuable!

The links that were promised:

Summit Therapeutics annouces its results in head to head against KEYTRUDA:

Seagen CEO David Epstein announces emergence of new company Ommito Pharma:

https://www.biopharmadive.com/news/ottimo-pharma-david-epstein-seagen-pd1-vegf-cancer-immunotherapy/731166

Abbvie and Evolveimmune:

https://www.fiercebiotech.com/biotech/abbvie-pays-65m-14b-chaser-options-evolveimmunes-t-cell-engagers

BioNTech acquisition of Biotheus:

https://www.biopharmadive.com/news/biontech-biotheus-pd1-vegf-bispecific-aquire-deal/732736

Merck’s acquisition of a PD-1 x VEGF bispecific from LaNova:

https://www.fiercebiotech.com/biotech/merck-pays-588m-bispecific-defend-keytrudas-kingdom-emerging-threat

My linkedin posts:

Summit Therapeutics’ data:

https://www.linkedin.com/posts/jeffrey-martin-oncology_big-news-in-immuno-oncology-top-immunotherapy-activity-7252292379829764096-Eg1B?utm_source=combined_share_message&utm_medium=member_desktop_web

NK Cell Engagers:

https://www.linkedin.com/posts/jeffrey-martin-oncology_the-natural-killer-cell-engager-field-is-activity-7246502771821092864-Rzot?utm_source=combined_share_message&utm_medium=member_desktop_web